TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17869296

Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil in patients with ASIA classification A and spinal cord injury above T6
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 15090124

Group type: EXPERIMENTAL
Intervention: Observer-reported implementation ratings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Provider self-reported implementation ratings
Number of subjects: 0
Study: 11308105

Group type: EXPERIMENTAL
Intervention: Mothers' arms
Number of subjects: 20

Group type: COMPARATOR
Intervention: Incubator
Number of subjects: 20
Study: 9041301

Group type: EXPERIMENTAL
Intervention: Intervention group viewed and received a copy of a videotape titled 'Feeding Your Baby With Love'
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (not explicitly described in the abstract)
Number of subjects: 59
Study: 8177844

Group type: EXPERIMENTAL
Intervention: Physical rehabilitation programme for 3 weeks including passive mobilization, respiratory exercises, and endurance exercise on an ergometric cycle.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no change in physical activity level).
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Physical rehabilitation programme for 3 weeks.
Number of subjects: 48
Study: 3109142

Group type: EXPERIMENTAL
Intervention: Nisoldipine (20 mg orally t.i.d. for 3 patients, 20 mg b.i.d. for 5 patients)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Captopril (25 mg orally t.i.d.)
Number of subjects: 17
Study: 30696556

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization
Number of subjects: 91

Group type: COMPARATOR
Intervention: Magnetic resonance imaging–guided focused ultrasound surgery
Number of subjects: 91
Study: 29636355

Group type: EXPERIMENTAL
Intervention: Family consultation (n=60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment-as-usual control (n=60)
Number of subjects: 120
Study: 28768069

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO₂) at 1.5 ATA for 60 minutes daily for 40 sessions
Number of subjects: 71

Group type: COMPARATOR
Intervention: Sham chamber sessions at 1.2 ATA, air for 60 minutes daily for 40 sessions
Number of subjects: 71
Study: 25179788

Group type: EXPERIMENTAL
Intervention: Plerixafor (MZ) given as a single dose to 30 poor mobilizers (PM)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: G‐CSF + Plerixafor (MZ)
Number of subjects: 90

Group type: COMPARATOR
Intervention: G‐CSF alone
Number of subjects: 90
Study: 22455385

Group type: EXPERIMENTAL
Intervention: Topical 1% oxytetracycline hydrochloride three times a day for 1 week
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 90
Study: 19174829

Group type: EXPERIMENTAL
Intervention: Whole Milk (WM)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Infant Formula
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Fish Oil
Number of subjects: 83

Group type: COMPARATOR
Intervention: No Fish Oil
Number of subjects: 83
Study: 17461394

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate
Number of subjects: 85

Group type: COMPARATOR
Intervention: Betamethasone diproprionate and betamethasone sodium phosphate
Number of subjects: 85
Study: 15918927

Group type: EXPERIMENTAL
Intervention: Self-reported vegetable and fruit intake categorized into groups: </=1 serving, 2-3 servings, and >/=4 servings per day
Number of subjects: 1598

Group type: EXPERIMENTAL
Intervention: Self-reported vegetable intake
Number of subjects: 1598
Study: 11817491

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 10634964

Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate 200 mg daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 7717315

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (325 mg)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Plain aspirin (325 mg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 47
Study: 2037955

Group type: EXPERIMENTAL
Intervention: Metronidazole treatment (250 mg tid for 7 days) plus debridement
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo treatment plus debridement (positive control)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Metronidazole treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo treatment (positive control)
Number of subjects: 39
Study: 6786566

Group type: EXPERIMENTAL
Intervention: Branded analgesic tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unbranded analgesic tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (inert formulation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active formulation (branded)
Number of subjects: 0
Study: 31426749

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/10 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: rosuvastatin 10 mg
Number of subjects: 50
Study: 28337563

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) combined with facial exercise treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Facial exercise treatment alone
Number of subjects: 46
Study: 26402762

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24088280

Group type: COMPARATOR
Intervention: Usual care (UC), distance <30 miles
Number of subjects: 503

Group type: COMPARATOR
Intervention: Usual care (UC), distance ≥30 miles
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Telemedicine, distance <30 miles
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Telemedicine, distance ≥30 miles
Number of subjects: 503
Study: 21867390

Group type: EXPERIMENTAL
Intervention: Enoxaparin 20 mg/0.2 ml subcutaneous (sc) 2 hr before surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no enoxaparin)
Number of subjects: 50
Study: 19626385

Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography (CCTA)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA) planned based on CCTA results
Number of subjects: 199
Study: 17760592

Group type: EXPERIMENTAL
Intervention: Intralesional steroids
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chemical peels
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Microdermabrasion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Blue or blue/red light combinations
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1,450-nm diode laser
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with 5-aminolevulinic acid or indocyanine green
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: New procedural therapies (radiofrequency, light or laser, photodynamic therapy)
Number of subjects: 10
Study: 15500555

Group type: EXPERIMENTAL
Intervention: 5 MU daily of IFN alfa‐2b for 4 weeks followed by IFN (5 MU TIW) plus ribavirin (1000/1200 mg/daily) for 48 weeks (group 1)
Number of subjects: 151

Group type: COMPARATOR
Intervention: 5 MU TIW of IFN alfa 2b for 4 weeks followed by IFN (5 MU TIW) plus ribavirin (1000/1200 mg/daily) for 48 weeks (group 2)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Overall SVR in patients with genotype 2/3
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Overall SVR in patients with genotype 1/4
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: SVR in genotype 1/4 patients younger than 40 years
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: SVR in genotype 1/4 patients older than 40 years
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Risk of nonresponse to retreatment in younger genotype 1/4 patients compared to genotype 2/3 patients
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Risk of nonresponse to retreatment in older genotype 1/4 patients compared to genotype 2/3 patients
Number of subjects: 151
Study: 11256836

Group type: EXPERIMENTAL
Intervention: Combined androgen blockade with UFT (400 mg/day)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Combined androgen blockade without UFT
Number of subjects: 142
Study: 10352494

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) therapy for 3 months
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline eosinophil percentage
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Change in FEV1% between baseline and post-treatment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Change of log Dmin
Number of subjects: 10
Study: 7655780

Group type: EXPERIMENTAL
Intervention: IL-2 (3 x 10(6) IU/day subcutaneously for 4 weeks) plus melatonin (40 mg/day orally)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 100
Study: 2403616

Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 38

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 38
Study: 642947

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)‐Aerosol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo‐aerosol
Number of subjects: 25
Study: 29624832

Group type: EXPERIMENTAL
Intervention: Metacognitive Interpersonal Therapy (MIT-G)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waiting list + Treatment as Usual (TAU)
Number of subjects: 20
Study: 28467116

Group type: EXPERIMENTAL
Intervention: Combined self-administered foot massage and CBT
Number of subjects: 53
Study: 25599690

Group type: EXPERIMENTAL
Intervention: Combined strategy intervention including printed information, treatment-compliance check cards, and text messages.
Number of subjects: 358

Group type: COMPARATOR
Intervention: Routine recommendations from physicians according to European clinical practice guidelines.
Number of subjects: 358
Study: 22846234

Group type: EXPERIMENTAL
Intervention: Self-checkout lanes
Number of subjects: 216
Study: 20863941

Group type: EXPERIMENTAL
Intervention: 2.0‐mm resorbable screws
Number of subjects: 11

Group type: COMPARATOR
Intervention: 1.5‐mm titanium screws
Number of subjects: 11
Study: 18216051

Group type: EXPERIMENTAL
Intervention: Free-flowing group (saline irrigation)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Streptokinase group (streptokinase irrigation)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Saline group (saline irrigation)
Number of subjects: 64
Study: 16153217

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 or 20 mg
Number of subjects: 2102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2102
Study: 14690014

Group type: EXPERIMENTAL
Intervention: Levamisole (80 mg every other day for 6 weeks) + rifampicin (600 mg/day) + doxycycline (200 mg/day) for 6 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (rifampicin 600 mg/day + doxycycline 200 mg/day for 6 weeks)
Number of subjects: 71
Study: 10378072

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (supervised 45-50 minute sessions, 85% of 1-RM, three days a week for 14 weeks)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 24
Study: 8616937

Group type: EXPERIMENTAL
Intervention: Colestipol/Niacin plus diet
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo plus diet
Number of subjects: 162
Study: 2069382

Group type: EXPERIMENTAL
Intervention: Loracarbef (LY163892) at 200 mg once daily (n = 53)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Cefaclor at 250 mg three times daily (n = 55)
Number of subjects: 108
Study: 6368355

Group type: EXPERIMENTAL
Intervention: +cyanidanol-3 (3 gm per day for 8 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 31314050

Group type: EXPERIMENTAL
Intervention: Simvastatin-Ezetimibe
Number of subjects: 2798

Group type: COMPARATOR
Intervention: Simvastatin-Placebo
Number of subjects: 2798
Study: 29710825

Group type: EXPERIMENTAL
Intervention: Specific amino acid composition with micronutrients
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 26931369

Group type: EXPERIMENTAL
Intervention: Gemcitabine and capecitabine combination chemotherapy with sequential telomerase GV1001 vaccine (n=18)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Gemcitabine and capecitabine combination chemotherapy with concomitant telomerase GV1001 vaccine (n=24)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Gemcitabine and capecitabine combination chemotherapy
Number of subjects: 38
Study: 24405830

Group type: EXPERIMENTAL
Intervention: Suboccipital muscle inhibition (SMI) technique for 4 minutes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham (placebo) intervention
Number of subjects: 40
Study: 22905596

Group type: EXPERIMENTAL
Intervention: High-dose hypoallergenic 6-grass pollen preparation (SCIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 20235638

Group type: EXPERIMENTAL
Intervention: AZT alone
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: AZT plus IFN-alpha
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: IFN-alpha alone
Number of subjects: 180
Study: 17097812

Group type: EXPERIMENTAL
Intervention: Patients with Graves' thyrotoxicosis
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Patients after reaching euthyroidism
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Patients 1 year after treatment initiation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 17140723

Group type: EXPERIMENTAL
Intervention: Nephron-sparing surgery (NSS)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Radical nephrectomy (RN)
Number of subjects: 541
Study: 15236831

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 11009132

Group type: EXPERIMENTAL
Intervention: Maryland WIC 5-A-Day Promotion Program (intervention)
Number of subjects: 3122

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3122
Study: 9366459

Group type: EXPERIMENTAL
Intervention: 0.25 microg x kg(‐1) x h(‐1) naloxone (low dose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 microg x kg(‐1) x h(‐1) naloxone (high dose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 60
Study: 1286492

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 115

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 115
Study: 3994348

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 254

Group type: COMPARATOR
Intervention: Moxalactam
Number of subjects: 254
Study: 30711295

Group type: EXPERIMENTAL
Intervention: Immediate loading of dental implants with bar overdentures (n=35)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional delayed loading protocol (n=16)
Number of subjects: 51
Study: 28973782

Group type: EXPERIMENTAL
Intervention: Cerebellar anodal transcranial direct current stimulation (a‐tDCS), 20 min, 1.5 mA
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 29
Study: 25627581

Group type: EXPERIMENTAL
Intervention: OptiBond FL (three‐step etch‐and‐rinse)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: OptiBond SOLO Plus (two‐step etch‐and‐rinse)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: OptiBond XTR (two‐step self‐etch)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: OptiBond All‐in One (one‐step self‐etch)
Number of subjects: 45
Study: 23525780

Group type: EXPERIMENTAL
Intervention: Healthy Bodies, Healthy Souls (HBHS) intervention
Number of subjects: 0
Study: 21499671

Group type: EXPERIMENTAL
Intervention: Participatory ergonomics (PE) program
Number of subjects: 3047

Group type: COMPARATOR
Intervention: Control group (no PE)
Number of subjects: 3047
Study: 19155011

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE, 0.625 mg/day)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: CEE (0.625 mg/day) plus medroxyprogesterone acetate (MPA, 2.5mg/day)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 17222641

Group type: EXPERIMENTAL
Intervention: Prolapse reduction
Number of subjects: 31

Group type: COMPARATOR
Intervention: Everted prolapse
Number of subjects: 31
Study: 15075543

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg, eight doses administered subcutaneously twice weekly beginning on day 4 of tuberculosis therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Historical controls (not specified)
Number of subjects: 16
Study: 11848191

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) only (Group 1, n = 8)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Scaling and root planing before splinting (Group 2, n = 10)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Scaling and root planing after splinting (Group 3, n = 11)
Number of subjects: 29
Study: 10021962

Group type: EXPERIMENTAL
Intervention: 27-G Quincke needle
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 27-G Whitacre needle
Number of subjects: 200

Group type: COMPARATOR
Intervention: General anaesthesia (comparative group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Women (subgroup)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Men (subgroup)
Number of subjects: 200
Study: 7512334

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 373

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 373
Study: 3228283

Group type: EXPERIMENTAL
Intervention: Active marijuana (2.3% delta 9 THC)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31841136

Group type: EXPERIMENTAL
Intervention: Continued bivalirudin infusion after PCI
Number of subjects: 13870

Group type: COMPARATOR
Intervention: No bivalirudin infusion after PCI
Number of subjects: 13870
Study: 31353231

Group type: EXPERIMENTAL
Intervention: Lipoprotein apheresis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 20
Study: 27503938

Group type: EXPERIMENTAL
Intervention: Decision aid for nutrition support
Number of subjects: 46
Study: 26011261

Group type: EXPERIMENTAL
Intervention: Electroacupuncture pretreatment (EAP)
Number of subjects: 388
Study: 23823815

Group type: EXPERIMENTAL
Intervention: IntraLase femtosecond laser
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Moria One Use‐Plus SBK
Number of subjects: 161

Group type: COMPARATOR
Intervention: Moria M2 Single‐Use 90 µm‐head microkeratome
Number of subjects: 161
Study: 21810165

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone 12 mg subcutaneous daily for 4 weeks
Number of subjects: 137
Study: 19524353

Group type: EXPERIMENTAL
Intervention: Pollen extract (Cernilton)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 16686911

Group type: EXPERIMENTAL
Intervention: Triptan treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Untreated migraine attacks
Number of subjects: 18
Study: 15560164

Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Hemosorption and plasmapheresis in one contour
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Efferent therapy after medication and photomodification of the blood
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Assisted reproductive technologies
Number of subjects: 289
Study: 12670352

Group type: COMPARATOR
Intervention: Desferrioxamine (DFX) alone (40‐50 mg/kg/d s.c. over 8‐12 h, five times weekly)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combined DFX twice weekly and deferiprone (75 mg/kg/d)
Number of subjects: 25
Study: 10955654

Group type: EXPERIMENTAL
Intervention: Trabecular aspiration with phacoemulsification and IOL implantation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard filtering glaucoma triple procedure (phaco‐trab)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Phaco‐trab group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Phaco‐aspiration group
Number of subjects: 40
Study: 8888670

Group type: EXPERIMENTAL
Intervention: Coronary stenting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticoagulation management
Number of subjects: 0
Study: 1443951

Group type: EXPERIMENTAL
Intervention: Education plus HIV testing
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Education alone
Number of subjects: 370

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 370
Study: 2859714

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30657232

Group type: EXPERIMENTAL
Intervention: Standardized Timed Up and Go (TUG) Test
Number of subjects: 30
Study: 29570164

Group type: EXPERIMENTAL
Intervention: Hypothermic machine perfusion (HMP)
Number of subjects: 752

Group type: COMPARATOR
Intervention: Static cold storage (CS)
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Cold ischemia time (CIT)
Number of subjects: 752
Study: 26826069

Group type: EXPERIMENTAL
Intervention: Time-pressure condition (mean response time = 96.00 seconds)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control condition (mean response time = 151.97 seconds)
Number of subjects: 42
Study: 24811615

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 593

Group type: COMPARATOR
Intervention: Diet plus physical activity
Number of subjects: 593
Study: 22385038

Group type: EXPERIMENTAL
Intervention: MicroPlaSter alpha device (2 min cold atmospheric argon plasma treatment)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MicroPlaSter beta device (2 min cold atmospheric argon plasma treatment)
Number of subjects: 24
Study: 20332772

Group type: EXPERIMENTAL
Intervention: Venlafaxine (75 mg hora somni)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 43
Study: 18329226

Group type: EXPERIMENTAL
Intervention: Gay-specific cognitive-behavioral therapy (GCBT, n = 64)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Gay-specific social support therapy (GSST, n = 64)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Both interventions (GCBT and GSST)
Number of subjects: 128
Study: 16143248

Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 56